Terns Pharmaceuticals appoints Robert Azelby to board; Carl Gordon resigns

Terns Pharmaceuticals, Inc.

Robert Azelby appointed to Board as Class I director effective Feb 20, 2025, and joins Compensation Committee.
Carl Gordon resigned from Board effective Feb 20, 2025 after over seven years; departure not due to disagreement.
Azelby brings 25+ years biopharma experience including CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals.
Azelby received option to purchase 90,000 shares vesting over three years under non-employee director compensation plan.
Company highlights TERN-701 for chronic myeloid leukemia and obesity programs approaching clinical readouts.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carl Gordon

Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2025-02-20
Filed: February 20, 2025, 6:59 PM ET

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Appointed

Robert Azelby

Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2025-02-20
Filed: February 20, 2025, 6:59 PM ET

On February 20, 2025, the Board appointed and elected Robert Azelby as a member of the Board, effective as of February 20, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl Gordon resigned as Director at Terns Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Azelby was appointed as Director at Terns Pharmaceuticals, Inc..

Action: appointed and elected
Role: Director

Exact text from the filing

On February 20, 2025, the Board appointed and elected Robert Azelby as a member of the Board, effective as of February 20, 2025.

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-024187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.